Exploring Mass Spectrometry Suitability to Examine Human Liver Graft Metabonomic Profiles
Autors de IIS La Fe
Grups d'Investigació
Abstract
Background. Transplant surgeons rely on morphologic aspects of the organ as well as clinical and histologic data to decide whether to use a graft. Metabonomics measures the "downstream" products of proteins and genes; these metabolic profiles are particularly good reporters of tissue physiologic features. Sample preparation and data acquisition are generally considered limiting steps in metabonome analysis because they are important sources of variability. State-of-the-art mass spectrometry and multivariate statistical analysis have been used to explore the suitability of a metabonomic platform as a liver tissue metabonomic profiling method. Objective. To develop robust and reliable sample processing and mass spectrometry protocols for studying human liver metabonomic profiles. Materials and Methods. Liquid chromatography coupled with mass spectrometry was used to analyze 20 liver tissue samples from 10 discarded and 10 transplanted grafts. Principal component analysis (PCA) and projection to latent structures discriminant analysis (PLS-DA) were used for data interpretation. Results. Standard operating protocols for sample processing (tissue homogenization) and data acquisition were developed. The quantification of the quality controls present in the test mix demonstrated coefficients of variation less than 15%. The PCA score plot revealed that the sample triplicate cluster was quite close. Furthermore, PLS-DA analysis demonstrated a clear separation (transplanted vs discarded) along the first component. Discussion. Multivariate data analysis (PCA and PLS-DA) indicated that protocols developed in-house for sample processing and mass spectrometry data acquisition were sufficiently sensitive (approximately 1245 features) and reproducible (sample triplicate clusters and test mix quantification) to perform liver tissue metabonomic profiling. In addition, a reduced set of metabolites was selected as potential biomarkers responsible for sample discrimination. These findings encourage ongoing research into the development of a metabonomic model to assess liver graft quality and function before transplantation.
Dades de la publicació
- ISSN/ISSNe:
- 0041-1345, 1873-2623
- Tipus:
- Article
- Pàgines:
- 2953-2958
- PubMed:
- 20970580
- Factor d'Impacte:
- 0,522 SCImago ℠
- Quartil:
- Q2 SCImago ℠
TRANSPLANTATION PROCEEDINGS ELSEVIER SCIENCE INC
Cites Rebudes en Web of Science: 11
Documents
- No hi ha documents
Filiacions
Filiacions no disponibles
Projectes associats
DESARROLLO DE UN MODELO HEPATOCELULAR HUMANO DIFERENCIADO PARA ESTUDIOS DE METABOLISMO Y POTENCIAL INDUCTOR DE NUEVOS FARMACOS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
SAF2003-09353 . 2003
A-CUTE-TOX
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
LSHB-CT-2004-512051-ACUTE TOX . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2005
DESARROLLO DE NUEVAS ESTRATEGIAS DIAGNOSTICAS BASADAS EN EL ESTUDIO DE LA CAPACIDAD METABOLIZANTE DE LA PIEL Y DEL PAPEL DE LAS CELULAS DENDITRICAS EN LA INDUCCION DE LAS REACCIONES ALERGICAS FRENTE A FARMACOS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
PARTIC PI05/2290 - FUND IMABIS . INSTITUTO DE SALUD CARLOS III; FUNDACION FIMABIS . 2007
DEVELOPMENT OF A HIGH THROUGHPUT GENOMICS-BASED TEST FOR ASSESSING GENOTOXIC AND CARCINOGENIC PROPERTIES OF CHEMICAL COMPOUNDS IN VITRO
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
CARCINOGENOMICS . COMISION EUROPEA . 2006
LINTOP
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
LSHB-CT-2006-037499 - LINTOP . FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2005
MECANISMOS TRNACRIPCIONALES IMPLICADOS EN LA ETIOLOGIA DEL HIGADO GRASO NO ALCOHOLICO. ESTUDIOS EN UN MODELO CELULAR HUMANO DE ESTEATOSIS Y APLICACION AL TRANSPLANTE DE HEPATOCITOS EN TERAPIA CELULAR.
Investigador Principal: RAMIRO JOVER ATIENZA
PI07/0550 . INSTITUTO DE SALUD CARLOS III . 2007
TU HOSPITAL INVESTIGA PARA TI
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
CCT005-07-00936 . 2007
PROYECTO CAIBER
CAI08/01/0061 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009
FORINVITOX
Investigador Principal: MARÍA JOSÉ GÓMEZ-LECHÓN MOLINER
FORINVITOX 1, START UP 2 . REMA; UNIVERSIDAD AUTONOMA BARCELONA; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2008
A SEARCH FOR A MULTIPARAMETRIC ASSESSMENT OF GRAFT PERFORMANCE PRIOR TO LIVER TRANSPLANT
CP08/00125 (MIGUEL SERVET) . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009
RED DE INNOVACION EN TECNOLOGIAS MEDICAS Y SANITARIAS - RED ITEMAS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
RD09/0077/00156 . INSTITUTO DE SALUD CARLOS III . 2010
CREACION Y MEJORA DE INFRAESTRUCTURAS EN MEDICINA REGENERATIVA
Investigador Principal: FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA
PLE2009-0141 ACI-PLAN E . MINISTERIO DE CIENCIA E INNOVACION; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2009
METABONOMICA Y CITOMICA COMO NUEVOS PARADIGMAS Y ESTRATEGIAS EXPERIMENTALES PARA EL ESTUDIO DE LOS MECANISMOS DE HEPATOTOXICIDAD DE FARMACOS, PREDICCION DE SU POTENCIAL HEPATOTOXICO Y LA TRANSICION DE HEPATITIS I ATROGENICA A AUTOINMUNE.
Investigador Principal: MARÍA TERESA DONATO MARTÍN
PI10/00923 . INSTITUTO DE SALUD CARLOS III . 2010
ESTUDIO MULTICENTRICO, ALEATORIZADO, ABIERTO Y CONTROLADO, DE 24 MESES DE SEGUIMIENTO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE EVEROLIMUS CON CONTROL DE LA CONCENTRACION PARA ELIMINAR O REDUCIR TACROLIMUS, EN COMPARACION CON TACROLIMUS, EN RECEPTORES DE TR ASPLANTE HEPATICO DE NOVO.
Investigador Principal: ANGEL MOYA HERRAIZ
CRAD001H2304 . 2008